BWXT Buys Kinectris
BWX Technologies, Inc. (NYSE: BWXT) announced that it has successfully completed its acquisition of Kinectrics, Inc. as of Tuesday. “Since we announced our intention to acquire Kinectrics in January, we have been looking forward to this day, when the complementary nature of our organizations begins to take shape,” said John MacQuarrie, BWXT president of Commercial Operations. “From the commercial nuclear power market to medical isotopes, we are enhancing our capabilities across the board, supporting a growing nuclear new build and life extension industry in Canada and strengthening BWXT’s position in the global nuclear market.”According to this morning’s news release, Kinectrics offers a broad suite of nuclear power plant lifecycle support services, including for CANDU reactors, and lifecycle management services for the global nuclear power industry, transmission and distribution markets and in the production and supply of isotopes for the radiopharmaceutical industry.The acquisition nearly doubles the workforce of BWXT’s Commercial Operations group and enables an expanded portfolio of products and services for current and new customers.Kinectrics will operate as a BWXT subsidiary, and its financial results will be reported within BWXT’s Commercial Operations segment. David Harris, president & CEO of Kinectrics, will lead the organization reporting to MacQuarrie.BWXT shares let go of 64 cents to $109.57.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


